Heme oxygenase system and hypertension: A comprehensive insight

Current Pharmaceutical Design

Volumn 20, Issue 9, 2014, Pages 1354-1369

  Tiwari, Shuchita ^a   Ndisang, Joseph Fomusi ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Adiponectin; Angiotensin induced hypertension; Bilirubin; Biliverdin; Carbon monoxide; Diabetic spontaneously hypertension; Essential hypertension; Ferritin; Fructose induced hypertension; Hemeoxygenase; Inflammation; Oxidative stress; Portal hypertension; Pulmonary hypertension; Renovascular hypertension; Salt induced hypertension

Indexed keywords

ADIPONECTIN; ALDOSTERONE; ANGIOTENSIN II; BILIRUBIN; BILIVERDIN; CARBON MONOXIDE; CYCLIC GMP; FERRITIN; FRUCTOSE; GUANYLATE CYCLASE; HEME ARGINATE; HEME OXYGENASE; HEME OXYGENASE 1; HEMIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PROTOPORPHYRIN COBALT; PROTOPORPHYRIN ZINC; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMALL INTERFERING RNA; VASODILATOR AGENT;

ANTIOXIDANT ACTIVITY; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CELL PROLIFERATION; CELL PROTECTION; DEOXYCORTICOSTERONE-SALT INDUCED HYPERTENSION; DIABETES MELLITUS; DISEASE MODEL; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; HEART FAILURE; HEART INFARCTION; HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERTROPHY; NEOINTIMA; NONHUMAN; OXIDATIVE STRESS; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RECEPTOR UPREGULATION; RENOVASCULAR HYPERTENSION; REPERFUSION INJURY; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR SMOOTH MUSCLE; VASODILATATION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; COMPLICATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BILIRUBIN; BILIVERDINE; CARBON MONOXIDE; FERRITINS; HEME OXYGENASE (DECYCLIZING); HEME OXYGENASE-1; HUMANS; HYPERTENSION; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84896336408     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990558     Document Type: Review

References (205)

1. Markou A, Pappa T, Kaltsas G, et al. Evidence of Primary Aldosteronism in a Predominantly Female Cohort of Normotensive Individuals: A Very High Odds Ratio for Progression into Arterial Hypertension. J Clin Endocrinol Metab 2013.
2. Scheurig-Muenkler C, Weiss W, Foert E, et al. Renal Denervation for Refractory Hypertension-Technical Aspects, Complications and Radiation Exposure. Rofo 2013.
3. Noone D, Licht C. Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options. Pediatr Nephrol 2013.
4. Kaneko K, Kawasaki T, Masunari S, Yoshida T, Omagari J. Determinants of Extraaortic Arterial 18F-FDG Accumulation in Asymptomatic Cohorts: Sex Differences in the Association with Cardiovascular Risk Factors and Coronary Artery Stenosis. J Nucl Med 2013.
5. Cereda CW, Tamisier R, Manconi M, et al. Endothelial Dysfunction and Arterial Stiffness in Ischemic Stroke: The Role of Sleep-Disordered Breathing. Stroke 2013.
6. Chaston DJ, Baillie BK, Grayson TH, et al. Polymorphism in Endothelial Connexin40 Enhances Sensitivity to Intraluminal Pressure and Increases Arterial Stiffness. Arterioscler Thromb Vasc Biol 2013.
7. Shimabukuro M, Hirata Y, Tabata M, et al. Epicardial Adipose Tissue Volume and Adipocytokine Imbalance Are Strongly Linked to Human Coronary Atherosclerosis. Arterioscler Thromb Vasc Biol 2013.
8. Borzych-Duzalka D, Bilginer Y, Ha IS, et al. Management of Anemia in Children Receiving Chronic Peritoneal Dialysis. J Am Soc Nephrol 2013.
9. Chang TY, Hwang BF, Liu CS, et al. Occupational Noise Exposure and Incident Hypertension in Men: A Prospective Cohort Study. Am J Epidemiol 2013.
10. Houssaini A, Abid S, Mouraret N, et al. Rapamycin Reverses Pulmonary-Artery Smooth-Muscle-Cell Proliferation in Pulmonary Hypertension. Am J Respir Cell Mol Biol 2013.
11. Ramkumar N, Stuart D, Ying J, Kohan DE. A possible interaction between systemic and renal angiotensinogen in the control of blood pressure. Am J Hypertens 2013; 26: 473-80.
12. Protogerou AD, Blacher J, Safar ME. Isolated systolic hypertension: 'to treat or not to treat' and the role of central haemodynamics. J Hypertens 2013; 31: 655-8.
13. Zou J, Li Y, Wang JG. The renal angiotensin system does not reveal its secrets with a cross-sectional analysis of urinary angiotensinogen levels. J Hypertens 2013; 31: 840-1.
14. Hong S, Lim JH, Jeong IG, Choe J, Kim CS, Hong JH. What association exists between hypertension and simple renal cyst in a screened population? J Hum Hypertens 2013.
15. Batis C, Gordon-Larsen P, Cole SR, Du S, Zhang B, Popkin B. Sodium Intake from Various Time Frames and Incident Hypertension Among Chinese Adults. Epidemiology 2013.
16. Zhang X, Zhu Z, Xu T, Shen Z. Factors Affecting Complete Hypertension Cure after Adrenalectomy for Aldosterone-Producing Adenoma: Outcomes in a Large Series. Urol Int 2013.
17. Salehi-Abargouei A, Maghsoudi Z, Shirani F, Azadbakht L. Effects of Dietary Approaches to Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases-Incidence: A systematic review and meta-analysis on observational prospective studies. Nutrition 2013; 29: 611-8.
18. Cao J, Drummond G, Inoue K, Sodhi K, Li XY, Omura S. Upregulation of Heme Oxygenase-1 Combined with Increased Adiponectin Lowers Blood Pressure in Diabetic Spontaneously Hypertensive Rats through a Reduction in Endothelial Cell Dysfunction, Apoptosis and Oxidative Stress. Int J Mol Sci 2008; 9: 2388-406.
19. Ram CV, Giles TD. The evolving definition of systemic arterial hypertension. Curr Atheroscler Rep 2010; 12: 155-8.
20. Kopp JB. Rethinking hypertensive kidney disease: arterionephrosclerosis as a genetic, metabolic, and inflammatory disorder. Curr Opin Nephrol Hypertens 2013.
21. Rodriguez-Flores M, Rodriguez-Saldana J, Cantu-Brito C, Aguirre-Garcia J, Alejandro GG. Prevalence and severity of atherosclerosis in different arterial territories and its relation with obesity. Cardiovasc Pathol 2013.
22. Solini A, Ruilope LM. How can resistant hypertension be identified and prevented? Nat Rev Cardiol 2013.
23. Bramlage P, Durand-Zaleski I, Desai N, Pirk O, Hacker C. The value of irbesartan in the management of hypertension. Expert Opin Pharmacother 2009; 10: 1817-31.
24. Leong XF, Mustafa MR, Das S, Jaarin K. Association of elevated blood pressure and impaired vasorelaxation in experimental Sprague-Dawley rats fed with heated vegetable oil. Lipids Health Dis 2010; 9: 66.
25. Lee CY, Yen MH. Nitric oxide and carbon monoxide, collaborative and competitive regulators of hypertension. Chang Gung Med J 2009; 32: 12-21.
26. Busk TM, Bendtsen F, Moller S. Cardiac and renal effects of a transjugular intrahepatic portosystemic shunt in cirrhosis. Eur J Gastroenterol Hepatol 2013.
27. Rossignol P, Cridlig J, Lehert P, Kessler M, Zannad F. Visit-tovisit blood pressure variability is a strong predictor of cardiovascular events in hemodialysis: insights from FOSIDIAL. Hypertension 2012; 60: 339-46.
28. Masoomi H, Kang CY, Chen A, et al. Predictive factors of inhospital mortality in colon and rectal surgery. J Am Coll Surg 2012; 215: 255-61.
29. Popolo A, Autore G, Pinto A, Marzocco S. Oxidative stress in cardiovascular disease and chronic renal failure. Free Radic Res 2013.
30. Staiculescu MC, Galinanes EL, Zhao G, et al. Prolonged vasoconstriction of resistance arteries involves vascular smooth muscle actin polymerization leading to inward remodelling. Cardiovasc Res 2013.
31. Roque FR, Briones AM, Garcia-Redondo AB, et al. Aerobic exercise reduces oxidative stress and improves vascular changes of small mesenteric and coronary arteries in hypertension. Br J Pharmacol 2013; 168: 686-703.
32. Pfisterer L, Feldner A, Hecker M, Korff T. Hypertension impairs myocardin function: a novel mechanism facilitating arterial remodelling. Cardiovasc Res 2012; 96: 120-9.
33. Yao J, Xiong M, Tang B, et al. Simvastatin attenuates pulmonary vascular remodelling by down-regulating matrix metalloproteinase-1 and-9 expression in a carotid artery-jugular vein shunt pulmonary hypertension model in rats. Eur J Cardiothorac Surg 2012; 42: e121-7.
34. Jadhav A, Ndisang JF. Heme arginate suppresses cardiac lesions and hypertrophy in deoxycorticosterone acetate-salt hypertension. Exp Biol Med (Maywood) 2009; 234: 764-78.
35. Ndisang JF, Jadhav A. Upregulating the heme oxygenase system suppresses left ventricular hypertrophy in adult spontaneously hypertensive rats for 3 months. J Card Fail 2009; 15: 616-28.
36. Ndisang JF, Jadhav A. Heme arginate therapy enhanced adiponectin and atrial natriuretic peptide, but abated endothelin-1 with attenuation of kidney histopathological lesions in mineralocorticoid-induced hypertension. J Pharmacol Exp Ther 2010; 334: 87-98.
37. Ndisang JF, Jadhav A. Heme-arginate suppresses phospholipase C and oxidative stress in the mesenteric arterioles of mineralcorticoid-induced hypertensive rats. Hypertens Res 2010; 33: 338-47.
38. Ndisang JF, Jadhav A, Lane N. Interaction between the heme oxygenase system and aldosterone in hypertension. Int J Angiol 2007; 16: 92-97.
39. Ndisang JF, Lane N, Jadhav A. Crosstalk between the heme oxygenase system, aldosterone, and phospholipase C in hypertension. J Hypertens 2008; 26: 1188-99.
40. Tosaki A, Das DK. The role of heme oxygenase signaling in various disorders. Mol Cell Biochem 2002; 232: 149-57.
41. Wagener FA, Volk HD, Willis D, et al. Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev 2003; 55: 551-71.
42. Lu Q, Yang Y, Villar VA, et al. D(5) dopamine receptor decreases NADPH oxidase, reactive oxygen species and blood pressure via heme oxygenase-1. Hypertens Res 2013.
43. Hassan N, El-Bassossy HM, Zakaria MN. Heme oxygenase-1 induction protects against hypertension associated with diabetes: effect on exaggerated vascular contractility. Naunyn Schmiedebergs Arch Pharmacol 2013; 386: 217-26.
44. Jadhav A, Tiwari S, Lee P, Ndisang JF. The heme oxygenase system selectively enhances the anti-inflammatory macrophage-M2 phenotype, reduces pericardial adiposity and ameliorated cardiac injury in diabetic cardiomyopathy in Zucker diabetic fatty rats. J Pharmacol Exp Ther 2013; 345: 239-49.
45. Jadhav A, Ndisang JF. Treatment with heme arginate alleviates adipose tissue inflammation and improves insulin sensitivity and glucose metabolism in a rat model of Human primary aldosteronism. Free Radic Biol Med 2012; 53: 2277-2286.
46. Jadhav A, Torlakovic E, Ndisang JF. Interaction Among Heme Oxygenase, Nuclear Factor-{kappa}B, and Transcription Activating Factors in Cardiac Hypertrophy in Hypertension. Hypertension 2008; 52: 910-917.
47. Jadhav A, Torlakovic E, Ndisang JF. Hemin therapy attenuates kidney injury in deoxycorticosterone acetate-salt hypertensive rats. Am J Physiol Renal Physiol 2009; 296: F521-F534.
48. Ndisang JF. Role of heme oxygenase in inflammation, insulinsignalling, diabetes and obesity. Mediators Inflamm 2010; 2010: 359732.
49. Ndisang JF, Baronti R, Cecere G, Masini E, Bani D, Mannaioni PF. Relaxin generates nitric oxide and provides protection against cardiac anaphylaxis. Inflamm Res 2001; 50 Suppl 2: S122-3.
50. Ndisang JF, Gai P, Berni L, et al. Modulation of the immunological response of guinea pig mast cells by carbon monoxide. Immunopharmacology 1999; 43: 65-73.
51. Ndisang JF, Jadhav A. Up-regulating the hemeoxygenase system enhances insulin sensitivity and improves glucose metabolism in insulin-resistant diabetes in Goto-Kakizaki rats. Endocrinology 2009; 150: 2627-36.
52. Ndisang JF, Jadhav A. Heme oxygenase system enhances insulin sensitivity and glucose metabolism in streptozotocin-induced diabetes. Am J Physiol Endocrinol Metab 2009; 296: E829-41.
53. Ndisang JF, Jadhav A. The heme oxygenase system attenuates pancreatic lesions and improves insulin sensitivity and glucose metabolism in deoxycorticosterone acetate hypertension. Am J Physiol Regul Integr Comp Physiol 2010; 298: R211-23.
54. Ndisang JF, Lane N, Jadhav A. The heme oxygenase system abates hyperglycemia in Zucker diabetic fatty rats by potentiating insulinsensitizing pathways. Endocrinology 2009; 150: 2098-108.
55. Ndisang JF, Lane N, Jadhav A. Upregulation of the heme oxygenase system ameliorates postprandial and fasting hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2009; 296: E1029-41.
56. Ndisang JF, Lane N, Syed N, Jadhav A. Up-regulating the heme oxygenase system with hemin improves insulin sensitivity and glucose metabolism in adult spontaneously hypertensive rats. Endocrinology 2010; 151: 549-60.
57. Ndisang JF, Moncini M, Gai P, et al. Induction of heme oxygenase provides protection against cardiac anaphylaxis. Inflamm Res 2000; 49 Suppl 1: S76-7.
58. Ndisang JF, Tabien HE, Wang R. Carbon monoxide and hypertension. J Hypertens 2004; 22: 1057-74.
59. Ndisang JF, Wang R. Age-related alterations in soluble guanylyl cyclase and cGMP pathway in spontaneously hypertensive rats. J Hypertens 2003; 21: 1117-24.
60. Ndisang JF, Wang R. Alterations in heme oxygenase/carbon monoxide system in pulmonary arteries in hypertension. Exp Biol Med (Maywood) 2003; 228: 557-63.
61. Ndisang JF, Wang R, Vannacci A, et al. Haeme oxygenase-1 and cardiac anaphylaxis. Br J Pharmacol 2001; 134: 1689-96.
62. Ndisang JF, Wu L, Zhao W, Wang R. Induction of heme oxygenase-1 and stimulation of cGMP production by hemin in aortic tissues from hypertensive rats. Blood 2003; 101: 3893-900.
63. Ndisang JF, Zhao W, Wang R. Selective regulation of blood pressure by heme oxygenase-1 in hypertension. Hypertension 2002; 40: 315-21.
64. Ndisang JF G, Berni L, Mirabella C, Baronti R, Mannaioni PF, Masini E. Modulation of the immunological response of guinea pig mast cells by carbon monoxide. Immunopharmacology 1999; 43 65-73.
65. Moreau R. Heme oxygenase: protective enzyme or portal hypertensive molecule? J Hepatol 2001; 34: 936-9.
66. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008; 60: 79-127.
67. George EM, Granger JP. Heme oxygenase in pregnancy and preeclampsia. Curr Opin Nephrol Hypertens 2013; 22: 156-62.
68. Barbagallo I, Galvano F, Frigiola A, et al. Potential therapeutic effects of natural heme oxygenase-1 inducers in cardiovascular diseases. Antioxid Redox Signal 2013; 18: 507-21.
69. Lonn ME, Dennis JM, Stocker R. Actions of "antioxidants" in the protection against atherosclerosis. Free Radic Biol Med 2012; 53: 863-84.
70. Chen YH, Yet SF, Perrella MA. Role of heme oxygenase-1 in the regulation of blood pressure and cardiac function. Exp Biol Med (Maywood) 2003; 228: 447-53.
71. Jansen T, Hortmann M, Oelze M, et al. Conversion of biliverdin to bilirubin by biliverdin reductase contributes to endothelial cell protection by heme oxygenase-1-evidence for direct and indirect antioxidant actions of bilirubin. J Mol Cell Cardiol 2010; 49: 186-95.
72. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997; 37: 517-54.
73. Sacerdoti D, Escalante B, Abraham NG, McGiff JC, Levere RD, Schwartzman ML. Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science 1989; 243: 388-90.
74. Wu L, Wang R. Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol Rev 2005; 57: 585-630.
75. L'Abbate A, Neglia D, Vecoli C, et al. Beneficial effect of heme oxygenase-1 expression on myocardial ischemia-reperfusion involves an increase in adiponectin in mildly diabetic rats. Am J Physiol Heart Circ Physiol 2007; 293: H3532-41.
76. Sabaawy HE, Zhang F, Nguyen X, et al. Human heme oxygenase-1 gene transfer lowers blood pressure and promotes growth in spontaneously hypertensive rats. Hypertension 2001; 38: 210-5.
77. Stevenson DK, Vreman HJ, Wong RJ, Dennery PA, Contag CH. Carbon monoxide detection and biological investigations. Trans Am Clin Climatol Assoc 2000; 111: 61-75.
78. Ortega-Saenz P, Pascual A, Gomez-Diaz R, Lopez-Barneo J. Acute oxygen sensing in heme oxygenase-2 null mice. J Gen Physiol 2006; 128: 405-11.
79. Zhang X, Shan P, Otterbein LE, et al. Carbon monoxide inhibition of apoptosis during ischemia-reperfusion lung injury is dependent on the p38 mitogen-activated protein kinase pathway and involves caspase 3. J Biol Chem 2003; 278: 1248-58.
80. Slebos DJ, Ryter SW, Choi AM. Heme oxygenase-1 and carbon monoxide in pulmonary medicine. Respir Res 2003; 4: 7.
81. Peterson SJ, Frishman WH, Abraham NG. Targeting heme oxygenase: therapeutic implications for diseases of the cardiovascular system. Cardiol Rev 2009; 17: 99-111.
82. Wilks A. Heme oxygenase: evolution, structure, and mechanism. Antioxid Redox Signal 2002; 4: 603-14.
83. Sikorski EM, Hock T, Hill-Kapturczak N, Agarwal A. The story so far: Molecular regulation of the heme oxygenase-1 gene in renal injury. Am J Physiol Renal Physiol 2004; 286: F425-41.
84. Hill-Kapturczak N, Chang SH, Agarwal A. Heme oxygenase and the kidney. DNA Cell Biol 2002; 21: 307-21.
85. Hill-Kapturczak N, Thamilselvan V, Liu F, Nick HS, Agarwal A. Mechanism of heme oxygenase-1 gene induction by curcumin in human renal proximal tubule cells. Am J Physiol Renal Physiol 2001; 281: F851-9.
86. Yet SF, Perrella MA, Layne MD, et al. Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice. J Clin Invest 1999; 103: R23-9.
87. Poss KD, Tonegawa S. Reduced stress defense in heme oxygenase 1-deficient cells. Proc Natl Acad Sci USA 1997; 94: 10925-30.
88. Nath KA. Heme oxygenase-1: a provenance for cytoprotective pathways in the kidney and other tissues. Kidney Int 2006; 70: 432-43.
89. Botros FT, Schwartzman ML, Stier CT, Jr., Goodman AI, Abraham NG. Increase in heme oxygenase-1 levels ameliorates renovascular hypertension. Kidney Int 2005; 68: 2745-55.
90. Hill-Kapturczak N, Sikorski E, Voakes C, Garcia J, Nick HS, Agarwal A. An internal enhancer regulates heme-and cadmiummediated induction of human heme oxygenase-1. Am J Physiol Renal Physiol 2003; 285: F515-23.
91. Exner M, Schillinger M, Minar E, et al. Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther 2001; 8: 433-40.
92. Soares MP, Bach FH. Heme oxygenase-1: from biology to therapeutic potential. Trends Mol Med 2009; 15: 50-8.
93. Inguaggiato P, Gonzalez-Michaca L, Croatt AJ, Haggard JJ, Alam J, Nath KA. Cellular overexpression of heme oxygenase-1 upregulates p21 and confers resistance to apoptosis. Kidney Int 2001; 60: 2181-91.
94. Ollinger R, Bilban M, Erat A, et al. Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation 2005; 112: 1030-9.
95. Fondevila C, Shen XD, Tsuchiyashi S, et al. Biliverdin therapy protects rat livers from ischemia and reperfusion injury. Hepatology 2004; 40: 1333-41.
96. Yamashita K, McDaid J, Ollinger R, et al. Biliverdin, a natural product of heme catabolism, induces tolerance to cardiac allografts. Faseb J 2004; 18: 765-7.
97. Sarady-Andrews JK, Liu F, Gallo D, et al. Biliverdin administration protects against endotoxin-induced acute lung injury in rats. Am J Physiol Lung Cell Mol Physiol 2005; 289: L1131-7.
98. Overhaus M, Moore BA, Barbato JE, Behrendt FF, Doering JG, Bauer AJ. Biliverdin protects against polymicrobial sepsis by modulating inflammatory mediators. Am J Physiol Gastrointest Liver Physiol 2006; 290: G695-703.
99. Gozzelino R, Jeney V, Soares MP. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol 2010; 50: 323-54.
100. Chin HJ, Song YR, Kim HS, et al. The bilirubin level is negatively correlated with the incidence of hypertension in normotensive Korean population. J Korean Med Sci 2009; 24 Suppl: S50-6.
101. Pachori AS, Smith A, McDonald P, Zhang L, Dzau VJ, Melo LG. Heme-oxygenase-1-induced protection against hypoxia/reoxygenation is dependent on biliverdin reductase and its interaction with PI3K/Akt pathway. J Mol Cell Cardiol 2007; 43: 580-92.
102. LeBlanc RM, Navar LG, Botros FT. Bilirubin exerts renoprotective effects in angiotensin II-hypertension. Am J Med Sci 2010; 340: 144-6.
103. Piantadosi CA. Biological chemistry of carbon monoxide. Antioxid Redox Signal 2002; 4: 259-70.
104. Cook MN, Nakatsu K, Marks GS, et al. Heme oxygenase activity in the adult rat aorta and liver as measured by carbon monoxide formation. Can J Physiol Pharmacol 1995; 73: 515-8.
105. McLaughlin BE, Chretien ML, Choi C, Brien JF, Nakatsu K, Marks GS. Potentiation of carbon monoxide-induced relaxation of rat aorta by YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole]. Can J Physiol Pharmacol 2000; 78: 343-9.
106. Leffler CW, Nasjletti A, Yu C, Johnson RA, Fedinec AL, Walker N. Carbon monoxide and cerebral microvascular tone in newborn pigs. Am J Physiol 1999; 276: H1641-6.
107. Wang R, Wu L, Wang Z. The direct effect of carbon monoxide on KCa channels in vascular smooth muscle cells. Pflugers Arch 1997; 434: 285-91.
108. McGrath JJ, Smith DL. Response of rat coronary circulation to carbon monoxide and nitrogen hypoxia. Proc Soc Exp Biol Med 1984; 177: 132-6.
109. Motterlini R, Gonzales A, Foresti R, Clark JE, Green CJ, Winslow RM. Heme oxygenase-1-derived carbon monoxide contributes to the suppression of acute hypertensive responses in vivo. Circ Res 1998; 83: 568-77.
110. Bucolo C, Drago F. Focus on molecules: heme oxygenase-1. Exp Eye Res 2009; 89: 822-3.
111. Fernandez M, Bonkovsky HL. Increased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats. Hepatology 1999; 29: 1672-9.
112. Vitali SH, Mitsialis SA, Liang OD, et al. Divergent cardiopulmonary actions of heme oxygenase enzymatic products in chronic hypoxia. PLoS One 2009; 4: e5978.
113. Dubuis E, Potier M, Wang R, Vandier C. Continuous inhalation of carbon monoxide attenuates hypoxic pulmonary hypertension development presumably through activation of BKCa channels. Cardiovasc Res 2005; 65: 751-61.
114. Brouard S, Otterbein LE, Anrather J, et al. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med 2000; 192: 1015-26.
115. Motterlini R, Sawle P, Hammad J, et al. CORM-A1: a new pharmacologically active carbon monoxide-releasing molecule. Faseb J 2005; 19: 284-6.
116. Stagni E, Privitera MG, Bucolo C, Leggio GM, Motterlini R, Drago F. A water-soluble carbon monoxide-releasing molecule (CORM-3) lowers intraocular pressure in rabbits. Br J Ophthalmol 2009; 93: 254-7.
117. Johnson FK, Johnson RA, Durante W, Jackson KE, Stevenson BK, Peyton KJ. Metabolic syndrome increases endogenous carbon monoxide production to promote hypertension and endothelial dysfunction in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 2006; 290: R601-8.
118. Teran FJ, Johnson RA, Stevenson BK, et al. Heme oxygenasederived carbon monoxide promotes arteriolar endothelial dysfunction and contributes to salt-induced hypertension in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 2005; 288: R615-22.
119. Wang R, Wu L. The chemical modification of KCa channels by carbon monoxide in vascular smooth muscle cells. J Biol Chem 1997; 272: 8222-6.
120. Ryter SW, Choi AM. Heme oxygenase-1/carbon monoxide: from metabolism to molecular therapy. Am J Respir Cell Mol Biol 2009; 41: 251-60.
121. Gerard C, Bruyns C, Marchant A, et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177: 547-50.
122. Soares MP, Brouard S, Smith RN, Bach FH. Heme oxygenase-1, a protective gene that prevents the rejection of transplanted organs. Immunol Rev 2001; 184: 275-85.
123. Petrache I, Otterbein LE, Alam J, Wiegand GW, Choi AM. Heme oxygenase-1 inhibits TNF-alpha-induced apoptosis in cultured fibroblasts. Am J Physiol Lung Cell Mol Physiol 2000; 278: L312-9.
124. Schuhmacher S, Wenzel P, Schulz E, et al. Pentaerythritol tetranitrate improves angiotensin II-induced vascular dysfunction via induction of heme oxygenase-1. Hypertension 2010; 55: 897-904.
125. Leffler CW, Parfenova H, Jaggar JH, Wang R. Carbon monoxide and hydrogen sulfide: gaseous messengers in cerebrovascular circulation. J Appl Physiol 2006; 100: 1065-76.
126. Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res 1999; 43: 521-31.
127. Pradhan A, Umezu M, Fukagawa M. Heme-oxygenase upregulation ameliorates angiotensin II-induced tubulointerstitial injury and salt-sensitive hypertension. Am J Nephrol 2006; 26: 552-61.
128. Cao J, Inoue K, Li X, Drummond G, Abraham NG. Physiological significance of heme oxygenase in hypertension. Int J Biochem Cell Biol 2009; 41: 1025-33.
129. Kojda G, Kottenberg K, Hacker A, Noack E. Alterations of the vascular and the myocardial guanylate cyclase/cGMP-system induced by long-term hypertension in rats. Pharm Acta Helv 1998; 73: 27-35.
130. Johnson RA, Lavesa M, DeSeyn K, Scholer MJ, Nasjletti A. Heme oxygenase substrates acutely lower blood pressure in hypertensive rats. Am J Physiol 1996; 271: H1132-8.
131. Anderson KE, Collins S. Open-label study of hemin for acute porphyria: clinical practice implications. Am J Med 2006; 119: e19-24.
132. Andersson C, Nilsson A, Backstrom T. Atypical attack of acute intermittent porphyria--paresis but no abdominal pain. J Intern Med 2002; 252: 265-70.
133. Johnson FK, Durante W, Peyton KJ, Johnson RA. Heme oxygenase inhibitor restores arteriolar nitric oxide function in dahl rats. Hypertension 2003; 41: 149-55.
134. Kozma F, Johnson RA, Zhang F, Yu C, Tong X, Nasjletti A. Contribution of endogenous carbon monoxide to regulation of diameter in resistance vessels. Am J Physiol 1999; 276: R1087-94.
135. Dworkin LD, Tolbert E, Recht PA, Hersch JC, Feiner H, Levin RI. Effects of amlodipine on glomerular filtration, growth, and injury in experimental hypertension. Hypertension 1996; 27: 245-50.
136. Katz SA, Opsahl JA, Wernsing SE, Forbis LM, Smith J, Heller LJ. Myocardial renin is neither necessary nor sufficient to initiate or maintain ventricular hypertrophy. Am J Physiol Regul Integr Comp Physiol 2000; 278: R578-86.
137. Shimamura T. 11-Deoxycorticosterone-induced hypertension, glomerulosclerosis and renal arterial and arteriolar lesions. Jpn J Exp Med 1988; 58: 225-8.
138. Gavras H, Brunner HR, Laragh JH, et al. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res 1975; 36: 300-9.
139. Ortiz PA, Garvin JL. Intrarenal transport and vasoactive substances in hypertension. Hypertension 2001; 38: 621-4.
140. Rodriguez JA, Lopez JM, Biglieri EG. DOCA test for aldosteronism: its usefulness and implications. Hypertension 1981; 3: 102-6.
141. Nath KA, d'Uscio LV, Juncos JP, et al. An analysis of the DOCAsalt model of hypertension in HO-1-/-mice and the Gunn rat. Am J Physiol Heart Circ Physiol 2007; 293: H333-42.
142. Alba G, El Bekay R, Chacon P, et al. Heme oxygenase-1 expression is down-regulated by angiotensin II and under hypertension in human neutrophils. J Leukoc Biol 2008; 84: 397-405.
143. Wenzel P, Daiber A, Oelze M, et al. Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis 2008; 198: 65-76.
144. Dikalova A, Clempus R, Lassegue B, et al. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005; 112: 2668-76.
145. Ndisang, J. F.; Masini, E.; Mannaioni, P. F.; Wang, R. In Carbon monoxide and cardiovascular functions; Wang R, ed.; CPC Press: Boca Raton, 2002, pp. 165-180.
146. Ndisang JF, Jadhav A. The heme oxygenase system attenuates pancreatic lesions and improves insulin sensitivity and glucose metabolism in deoxycorticosterone acetate hypertension. Am J Physiol Regul Integr Comp Physiol 2010; 298: R1444-5.
147. Vera T, Kelsen S, Stec DE. Kidney-specific induction of heme oxygenase-1 prevents angiotensin II hypertension. Hypertension 2008; 52: 660-5.
148. Cao J, Sodhi K, Inoue K, et al. Lentiviral-human heme oxygenase targeting endothelium improved vascular function in angiotensin II animal model of hypertension. Hum Gene Ther 2011; 22: 271-82.
149. Dai S, McNeill JH. Fructose-induced hypertension in rats is concentration-and duration-dependent. J Pharmacol Toxicol Methods 1995; 33: 101-7.
150. Polizio AH, Gonzales S, Munoz MC, Pena C, Tomaro ML. Behaviour of the anti-oxidant defence system and heme oxygenase-1 protein expression in fructose-hypertensive rats. Clin Exp Pharmacol Physiol 2006; 33: 734-9.
151. Yu X, Tao W, Jiang F, Li C, Lin J, Liu C. Celastrol attenuates hypertension-induced inflammation and oxidative stress in vascular smooth muscle cells via induction of heme oxygenase-1. Am J Hypertens 2010; 23: 895-903.
152. Bosch J, Pizcueta P, Feu F, Fernandez M, Garcia-Pagan JC. Pathophysiology of portal hypertension. Gastroenterol Clin North Am 1992; 21: 1-14.
153. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009; 49: 1245-56.
154. Odaka Y, Takahashi T, Yamasaki A, et al. Prevention of halothaneinduced hepatotoxicity by hemin pretreatment: protective role of heme oxygenase-1 induction. Biochem Pharmacol 2000; 59: 871-80.
155. Matsumi M, Takahashi T, Fujii H, et al. Increased heme oxygenase-1 gene expression in the livers of patients with portal hypertension due to severe hepatic cirrhosis. J Int Med Res 2002; 30: 282-8.
156. Shimizu H, Takahashi T, Suzuki T, et al. Protective effect of heme oxygenase induction in ischemic acute renal failure. Crit Care Med 2000; 28: 809-17.
157. Erario MA, Gonzales S, Romay S, et al. Role of heme oxygenase/carbon monoxide pathway on the vascular response to noradrenaline in portal hypertensive rats. Clin Exp Pharmacol Physiol 2005; 32: 196-201.
158. Lin HH, Chen YH, Yet SF, Chau LY. Heme oxygenase-1/carbon monoxide enhances reendothelialization after vascular injury via promoting mobilization of circulating endothelial progenitor cells. J Thromb Haemost 2009.
159. Cao L, Arany PR, Wang YS, Mooney DJ. Promoting angiogenesis via manipulation of VEGF responsiveness with notch signaling. Biomaterials 2009.
160. Sambuceti G, Morbelli S, Vanella L, et al. Diabetes Impairs the Vascular Recruitment of Normal Stem Cells by Oxidant Damage; Reversed by Increases in pAMPK, Heme Oxygenase-1 and Adiponectin. Stem Cells 2008.
161. Lin HH, Chen YH, Chang PF, Lee YT, Yet SF, Chau LY. Heme oxygenase-1 promotes neovascularization in ischemic heart by coinduction of VEGF and SDF-1. J Mol Cell Cardiol 2008; 45: 44-55.
162. Angermayr B, Mejias M, Gracia-Sancho J, Garcia-Pagan JC, Bosch J, Fernandez M. Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats. J Hepatol 2006; 44: 1033-9.
163. Tiani C, Garcia-Pras E, Mejias M, de Gottardi A, Berzigotti A, Bosch J, Fernandez M. Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension. J Hepatol 2009; 50: 296-305.
164. Gonzales S, Perez MJ, Perazzo JC, Tomaro ML. Antioxidant role of heme oxygenase-1 in prehepatic portal hypertensive rats. World J Gastroenterol 2006; 12: 4149-55.
165. Tarquini R, Masini E, La Villa G, et al. Increased plasma carbon monoxide in patients with viral cirrhosis and hyperdynamic circulation. Am J Gastroenterol 2009; 104: 891-7.
166. Van Landeghem L, Laleman W, Vander Elst I, et al. Carbon monoxide produced by intrasinusoidally located haem-oxygenase-1 regulates the vascular tone in cirrhotic rat liver. Liver Int 2009; 29: 650-60.
167. Wiesel P, Patel AP, Carvajal IM, et al. Exacerbation of chronic renovascular hypertension and acute renal failure in heme oxygenase-1-deficient mice. Circ Res 2001; 88: 1088-94.
168. Minamino T, Christou H, Hsieh CM, et al. Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci USA 2001; 98: 8798-803.
169. Kourembanas S. Hypoxia and carbon monoxide in the vasculature. Antioxid Redox Signal 2002; 4: 291-9.
170. Li M, Kim DH, Tsenovoy PL, et al. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes 2008; 57: 1526-35.
171. Ito T, Okada T, Miyashita H, et al. Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats. Circ Res 2007; 101: 734-41.
172. Zhou H, Liu H, Porvasnik SL, et al. Heme oxygenase-1 mediates the protective effects of rapamycin in monocrotaline-induced pulmonary hypertension. Lab Invest 2006; 86: 62-71.
173. Hsu HH, Ko WJ, Hsu JY, Chen JS, Lee YC, Lai IR, Chen CF. Simvastatin ameliorates established pulmonary hypertension through a heme oxygenase-1 dependent pathway in rats. Respir Res 2009; 10: 32.
174. Hsu HH, Ruan T, Ko WJ, et al. Effects of simvastatin on pulmonary C-fiber sensitivity in rats with monocrotaline-induced pulmonary hypertension. J Heart Lung Transplant 2011; 30: 332-40.
175. Nicolai A, Li M, Kim DH, et al. Heme oxygenase-1 induction remodels adipose tissue and improves insulin sensitivity in obesityinduced diabetic rats. Hypertension 2009; 53: 508-15.
176. Platt JL, Nath KA. Heme oxygenase: protective gene or Trojan horse. Nat Med 1998; 4: 1364-5.
177. Dennery PA. Regulation and role of heme oxygenase in oxidative injury. Curr Top Cell Regul 2000; 36: 181-99.
178. Zager RA. Heme protein-induced tubular cytoresistance: expression at the plasma membrane level. Kidney Int 1995; 47: 1336-45.
179. Zhang J, Piantadosi CA. Mitochondrial oxidative stress after carbon monoxide hypoxia in the rat brain. J Clin Invest 1992; 90: 1193-9.
180. Tsuda K. Roles of adiponectin and oxidative stress in the regulation of membrane microviscosity of red blood cells in hypertensive men-an electron spin resonance study. J Obes 2011; pii:548140.
181. Hill-Kapturczak N, Truong L, Thamilselvan V, Visner GA, Nick HS, Agarwal A. Smad7-dependent regulation of heme oxygenase-1 by transforming growth factor-beta in human renal epithelial cells. J Biol Chem 2000; 275: 40904-9.
182. Johnson FK, Durante W, Peyton KJ, Johnson RA. Heme oxygenase-mediated endothelial dysfunction in DOCA-salt, but not in spontaneously hypertensive, rat arterioles. Am J Physiol Heart Circ Physiol 2004; 286: H1681-7.
183. Haugen EN, Croatt AJ, Nath KA. Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro. Kidney Int 2000; 58: 144-52.
184. Sarady JK, Zuckerbraun BS, Bilban M, et al. Carbon monoxide protection against endotoxic shock involves reciprocal effects on iNOS in the lung and liver. Faseb J 2004; 18: 854-6.
185. Taille C, El-Benna J, Lanone S, Boczkowski J, Motterlini R. Mitochondrial respiratory chain and NAD(P)H oxidase are targets for the antiproliferative effect of carbon monoxide in human airway smooth muscle. J Biol Chem 2005; 280: 25350-60.
186. Botros FT, Navar LG. Interaction between endogenously produced carbon monoxide and nitric oxide in regulation of renal afferent arterioles. Am J Physiol Heart Circ Physiol 2006; 291: H2772-8.
187. Durante W, Kroll MH, Christodoulides N, Peyton KJ, Schafer AI. Nitric oxide induces heme oxygenase-1 gene expression and carbon monoxide production in vascular smooth muscle cells. Circ Res 1997; 80: 557-64.
188. Forstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch 2010; 459: 923-39.
189. Avihingsanon Y, Ma N, Csizmadia E, et al. Expression of protective genes in human renal allografts: a regulatory response to injury associated with graft rejection. Transplantation 2002; 73: 1079-85.
190. Alcaraz MJ, Habib A, Creminon C, et al. Heme oxygenase-1 induction by nitric oxide in RAW 264.7 macrophages is upregulated by a cyclo-oxygenase-2 inhibitor. Biochim Biophys Acta 2001; 1526: 13-6.
191. Schulz R, Rassaf T, Massion PB, Kelm M, Balligand JL. Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis. Pharmacol Ther 2005; 108: 225-56.
192. Raij L. Nitric oxide in hypertension: relationship with renal injury and left ventricular hypertrophy. Hypertension 1998; 31: 189-93.
193. Mandal P, Pritchard MT, Nagy LE. Anti-inflammatory pathways and alcoholic liver disease: role of an adiponectin/interleukin-10/heme oxygenase-1 pathway. World J Gastroenterol 2010; 16: 1330-6.
194. Diez JJ, Iglesias P. The role of the novel adipocyte-derived protein adiponectin in human disease: an update. Mini Rev Med Chem 2010; 10: 856-69.
195. Cao Y, Tao L, Yuan Y, et al. Endothelial dysfunction in adiponectin deficiency and its mechanisms involved. J Mol Cell Cardiol 2009; 46: 413-9.
196. Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118: 1645-56.
197. Cao J, Sodhi K, Inoue K, et al. Lentiviral-human heme oxygenase targeting endothelium improved vascular function in angiotensin II animal model of hypertension. Hum Gene Ther 2010; 22: 271-82.
198. Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res 2007; 74: 11-8.
199. Ali F, Hamdulay SS, Kinderlerer AR, et al. Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. J Thromb Haemost 2007; 5: 2537-46.
200. Pflueger A, Croatt AJ, Peterson TE, et al. The hyperbilirubinemic Gunn rat is resistant to the pressor effects of angiotensin II. Am J Physiol Renal Physiol 2005; 288: F552-8.
201. Nath KA, Balla G, Vercellotti GM, et al. Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. J Clin Invest 1992; 90: 267-70.
202. Agarwal A, Balla J, Alam J, Croatt AJ, Nath KA. Induction of heme oxygenase in toxic renal injury: a protective role in cisplatin nephrotoxicity in the rat. Kidney Int 1995; 48: 1298-307.
203. Shiraishi F, Curtis LM, Truong L, et al. Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. Am J Physiol Renal Physiol 2000; 278: F726-36.
204. Elmarakby AA, Quigley JE, Imig JD, Pollock JS, Pollock DM. TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2008; 294: R76-83.
205. Tanous D, Brasen JH, Choy K, et al. Probucol inhibits in-stent thrombosis and neointimal hyperplasia by promoting reendothelialization. Atherosclerosis 2006; 189: 342-9.